<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02293551</url>
  </required_header>
  <id_info>
    <org_study_id>15626</org_study_id>
    <secondary_id>F3Z-FW-ITCA</secondary_id>
    <nct_id>NCT02293551</nct_id>
  </id_info>
  <brief_title>A Study of Lispro Formulations in Healthy Participants</brief_title>
  <official_title>Safety, Tolerability, and Pharmacokinetics of Multiple Novel Insulin Lispro Formulations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are to determine:

        -  Part A

             -  How quickly your body absorbs, breaks down and gets rid of the different
                formulations of insulin lispro compared to insulin lispro alone formulation.

             -  The safety of insulin lispro in different formulations and any side effects that
                might be associated with it.

        -  Part B:

             -  How much insulin lispro from different dose ranges is found in the bloodstream
                using a test insulin lispro formulation (selected from Part A).

             -  The safety of insulin lispro in different formulations and any side effects that
                might be associated with it.

      Participants may only enroll in one part. The study is expected to last up to 10 weeks for
      each part.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A and B: Pharmacokinetics: Area Under The Concentration Curve (AUC) of LY275585</measure>
    <time_frame>Predose through day 1 in each period</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Part A: Lispro (A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formulation A: Single dose of lispro administered subcutaneously (SC) in one of five periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Lispro (B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formulation B: Single dose of lispro administered SC in one of five periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Lispro (C)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formulation C: Single dose of lispro administered SC in one of five periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Lispro (D)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formulation D: Single dose of lispro administered SC in one of five periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Lispro (Reference)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reference formulation: Single dose of lispro administered SC in one of five periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Lispro</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formulation selected from Part A. Single dose of lispro administered SC in one of four periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lispro</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Part A: Lispro (A)</arm_group_label>
    <arm_group_label>Part A: Lispro (B)</arm_group_label>
    <arm_group_label>Part A: Lispro (C)</arm_group_label>
    <arm_group_label>Part A: Lispro (D)</arm_group_label>
    <arm_group_label>Part A: Lispro (Reference)</arm_group_label>
    <arm_group_label>Part B: Lispro</arm_group_label>
    <other_name>LY275585</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Overtly healthy males or females (nonchildbearing potential and with absent cyclical
        hormonal changes), as determined by medical history and physical examination

        Exclusion Criteria:

        - Have a fasting plasma glucose less than or equal to (≤) 4.0 millimole per liter (mmol/L)
        at screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1‐877‐CTLILLY (1‐877‐285‐4559) or 1‐317‐615‐4559 Mon ‐ Fri 9 AM ‐ 5 PM Eastern time (UTC/GMT ‐ 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1‐877‐CTLILLY (1‐877‐285‐4559, 1‐317‐615‐4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT ‐ 5 hours, EST) or speak with your personal physician.</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2014</study_first_submitted>
  <study_first_submitted_qc>November 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2014</study_first_posted>
  <last_update_submitted>September 8, 2015</last_update_submitted>
  <last_update_submitted_qc>September 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

